PT3211005T - Utilização terapêutica de ligandos específicos nas doenças associadas a msrv - Google Patents

Utilização terapêutica de ligandos específicos nas doenças associadas a msrv

Info

Publication number
PT3211005T
PT3211005T PT171596992T PT17159699T PT3211005T PT 3211005 T PT3211005 T PT 3211005T PT 171596992 T PT171596992 T PT 171596992T PT 17159699 T PT17159699 T PT 17159699T PT 3211005 T PT3211005 T PT 3211005T
Authority
PT
Portugal
Prior art keywords
msrv
diseases associated
therapeutic use
specific ligands
ligands
Prior art date
Application number
PT171596992T
Other languages
English (en)
Original Assignee
Geneuro Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Geneuro Sa filed Critical Geneuro Sa
Publication of PT3211005T publication Critical patent/PT3211005T/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
PT171596992T 2008-07-08 2009-07-08 Utilização terapêutica de ligandos específicos nas doenças associadas a msrv PT3211005T (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12961308P 2008-07-08 2008-07-08
US20258109P 2009-03-13 2009-03-13
US21318909P 2009-05-15 2009-05-15

Publications (1)

Publication Number Publication Date
PT3211005T true PT3211005T (pt) 2021-06-15

Family

ID=41165692

Family Applications (2)

Application Number Title Priority Date Filing Date
PT97803118T PT2315777T (pt) 2008-07-08 2009-07-08 Uso terapêutico de ligandos específicos nas doenças associadas a msrv
PT171596992T PT3211005T (pt) 2008-07-08 2009-07-08 Utilização terapêutica de ligandos específicos nas doenças associadas a msrv

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PT97803118T PT2315777T (pt) 2008-07-08 2009-07-08 Uso terapêutico de ligandos específicos nas doenças associadas a msrv

Country Status (24)

Country Link
US (4) US8715656B2 (pt)
EP (2) EP3211005B1 (pt)
JP (3) JP6058264B2 (pt)
KR (1) KR101682040B1 (pt)
CN (1) CN102143975B (pt)
AU (1) AU2009268025B2 (pt)
BR (1) BRPI0915667B8 (pt)
CA (1) CA2729869C (pt)
CY (2) CY1119185T1 (pt)
DK (1) DK3211005T3 (pt)
EA (1) EA024655B1 (pt)
ES (2) ES2633965T3 (pt)
HR (2) HRP20171067T1 (pt)
HU (2) HUE033803T2 (pt)
IL (1) IL210204A (pt)
LT (2) LT3211005T (pt)
MX (1) MX2010014319A (pt)
NZ (1) NZ590515A (pt)
PL (2) PL3211005T3 (pt)
PT (2) PT2315777T (pt)
SI (2) SI2315777T1 (pt)
SM (1) SMT201700366T1 (pt)
WO (1) WO2010003977A1 (pt)
ZA (1) ZA201100446B (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE536374T1 (de) 2006-09-01 2011-12-15 Therapeutic Human Polyclonals Inc Erhöhte expression von humanem oder humanisiertem immunglobulin bei nicht-humanen transgenen tieren
JP6058264B2 (ja) * 2008-07-08 2017-01-11 ジェウヌロ・エスエーＧｅＮｅｕｒｏ ＳＡ Ｍｓｒｖ関連疾患の特異的なリガンドの治療上の使用
FR2945538B1 (fr) * 2009-05-12 2014-12-26 Sanofi Aventis Anticorps humanises specifiques de la forme protofibrillaire du peptide beta-amyloide.
UA119032C2 (uk) * 2012-10-02 2019-04-25 Женеро Са Фармацевтична композиція для лікування блокади ремієлінізації при захворюваннях, які пов'язані з експресією білка оболонки herv-w
EP2949342A1 (en) * 2014-05-28 2015-12-02 Geneuro SA Antiretroviral drug targeting human endogenous retrovirus
CN113862300A (zh) * 2015-10-29 2021-12-31 豪夫迈·罗氏有限公司 具有共同轻链的转基因兔
JP2018028538A (ja) * 2016-08-12 2018-02-22 公立大学法人名古屋市立大学 統合失調症とその関連疾患の診断用マーカー及びその使用
WO2019201908A1 (en) 2018-04-17 2019-10-24 Geneuro Sa Method for the detection of the soluble hydrophilic oligomeric form of herv-w envelope protein
EP3916015A1 (en) * 2020-05-28 2021-12-01 Geneuro SA Anti-herv-w envelope protein antibody for use in the treatment of psychotic diseases
CN113940993B (zh) * 2021-12-20 2022-02-22 深圳万可森生物科技有限公司 一种鲈鱼弹状病毒g2-2m亚单位疫苗及其制备方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4945050A (en) 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
WO1991002071A2 (en) 1989-08-09 1991-02-21 Dekalb Plant Genetics Methods and compositions for the production of stably transformed, fertile monocot plants and cells thereof
US7705215B1 (en) 1990-04-17 2010-04-27 Dekalb Genetics Corporation Methods and compositions for the production of stably transformed, fertile monocot plants and cells thereof
US7473423B2 (en) * 1994-04-29 2009-01-06 Mayo Foundation For Medical Education And Research Human IgM antibodies, and diagnostic and therapeutic uses thereof particularly in the central nervous system
FR2734842B1 (fr) 1995-06-02 1998-02-27 Rhone Poulenc Agrochimie Sequence adn d'un gene de l'hydroxy-phenyl pyruvate dioxygenase et obtention de plantes contenant un gene de l'hydroxy-phenyl pyruvate dioxygenase, tolerantes a certains herbicides
FR2736926B1 (fr) 1995-07-19 1997-08-22 Rhone Poulenc Agrochimie 5-enol pyruvylshikimate-3-phosphate synthase mutee, gene codant pour cette proteine et plantes transformees contenant ce gene
EP1224291A1 (en) * 1999-10-28 2002-07-24 Universite De Geneve Multiple sclerosis-related superantigen
KR20060015602A (ko) * 2003-05-31 2006-02-17 마이크로메트 에이지 ＥｐＣＡＭ 에 대한 이중 특이성 항체를 포함하는약학조성물
FR2865403B1 (fr) * 2004-01-23 2009-06-12 Biomerieux Sa Composition pour le traitement d'une pathologie associee a la msrv/herv-w
CN1842540B (zh) 2004-07-09 2012-07-04 中外制药株式会社 抗-磷脂酰肌醇蛋白聚糖3抗体
US7579187B2 (en) 2004-09-06 2009-08-25 Kyoma Hakko Kirin Co., Ltd. Anti-A33 antibody
EP1829961A4 (en) 2004-12-22 2008-06-04 Chugai Pharmaceutical Co Ltd METHOD FOR THE PRODUCTION OF AN ANTIBODY USING A CELL WITH HARDENED FUCOSET TRANSPORT FUNCTION
WO2006138627A2 (en) 2005-06-16 2006-12-28 Inhibitex, Inc. Monoclonal antibodies recognizing a coagulase-negative staphylococcal protein
WO2006137354A1 (ja) 2005-06-21 2006-12-28 Medical & Biological Laboratories Co., Ltd. アミロイド線維形成に対する阻害活性を有する抗体
FR2912314B1 (fr) * 2007-02-09 2012-08-03 Geneuro Sa Composition pharmaceutique comprenant des anticorps diriges contre l'enveloppe de herv-w.
JP6058264B2 (ja) * 2008-07-08 2017-01-11 ジェウヌロ・エスエーＧｅＮｅｕｒｏ ＳＡ Ｍｓｒｖ関連疾患の特異的なリガンドの治療上の使用

Also Published As

Publication number Publication date
HK1158232A1 (en) 2012-07-13
PL2315777T3 (pl) 2017-10-31
AU2009268025A1 (en) 2010-01-14
US9815888B2 (en) 2017-11-14
SMT201700366T1 (it) 2017-09-07
JP6109869B2 (ja) 2017-04-05
US10059758B2 (en) 2018-08-28
HUE033803T2 (en) 2018-01-29
EP2315777B1 (en) 2017-04-26
KR20110031969A (ko) 2011-03-29
EP3211005A1 (en) 2017-08-30
JP2011527887A (ja) 2011-11-10
BRPI0915667B1 (pt) 2020-10-13
PL3211005T3 (pl) 2021-11-29
US8715656B2 (en) 2014-05-06
LT2315777T (lt) 2017-10-25
HRP20171067T1 (hr) 2017-10-06
CA2729869A1 (en) 2010-01-14
JP6058264B2 (ja) 2017-01-11
EA201100160A1 (ru) 2011-08-30
CY1119185T1 (el) 2018-02-14
JP6495361B2 (ja) 2019-04-03
EP2315777A1 (en) 2011-05-04
AU2009268025B2 (en) 2014-07-31
CN102143975A (zh) 2011-08-03
IL210204A (en) 2015-03-31
JP2017158550A (ja) 2017-09-14
US20180057569A1 (en) 2018-03-01
ES2875762T3 (es) 2021-11-11
US9550824B2 (en) 2017-01-24
CY1124281T1 (el) 2022-07-22
US20140220026A1 (en) 2014-08-07
CA2729869C (en) 2018-02-13
JP2015157812A (ja) 2015-09-03
LT3211005T (lt) 2021-08-25
IL210204A0 (en) 2011-03-31
HK1243436A1 (en) 2018-07-13
HRP20210892T1 (hr) 2021-11-26
KR101682040B1 (ko) 2016-12-02
US20170107274A1 (en) 2017-04-20
EA024655B1 (ru) 2016-10-31
MX2010014319A (es) 2011-05-19
US20110243962A1 (en) 2011-10-06
HUE054712T2 (hu) 2021-09-28
NZ590515A (en) 2013-01-25
BRPI0915667B8 (pt) 2021-05-25
WO2010003977A1 (en) 2010-01-14
CN102143975B (zh) 2014-12-31
ES2633965T3 (es) 2017-09-26
PT2315777T (pt) 2017-07-25
ZA201100446B (en) 2012-01-25
SI3211005T1 (sl) 2021-06-30
BRPI0915667A2 (pt) 2017-01-17
EP3211005B1 (en) 2021-03-17
SI2315777T1 (sl) 2017-09-29
DK3211005T3 (da) 2021-06-07

Similar Documents

Publication Publication Date Title
IL271083A (en) Humanized fcgammar mice
PT3211005T (pt) Utilização terapêutica de ligandos específicos nas doenças associadas a msrv
EP2533634A4 (en) NERVE PROTECTION FOR DESCALE DISEASES
HRP20160551T8 (hr) Kombinirana terapija s pripravcima nanočestica taksana i hedgehog inhibitora
IL233023A (en) Method of characterizing a cancer in a subject
DK2131906T3 (da) Emballeret brugsklart intraluminalt kateter
BRPI0916931A2 (pt) agentes terapêuticos
SI2619576T1 (sl) Sredstva in metode za predvidevanje odziva rakavega pacienta na zdravljenje
BRPI0920514A2 (pt) infusão de fármacos
PL3005986T3 (pl) Infuzja leków
HUE047767T2 (hu) Macitentánt tartalmazó terápiás készítmények
SMT201600263B (it) Regimi terapeutici
BRPI0920743A2 (pt) ribonucleases terapeuticas
BRPI0818598A2 (pt) agentes terapêuticos - 802
BR112014015468A2 (pt) produto absorvente descartável com regiões laterais ligadas e métodos relacionados
EP2438167A4 (en) THERAPEUTIC AND DIAGNOSTIC MOLECULES
BRPI0714318A2 (pt) Utilização de 2-benzoil-imidazopiridinas em terapêutica
EP2424529A4 (en) NEW THERAPEUTIC TREATMENTS USING CENTHAQUIN
PT2670769T (pt) R2r1/2 em diagnóstico e terapêutica
HRP20151393T8 (hr) UPORABA BENZIDAMINA U LIJEČENJU BOLESTI KOJE SU p40-OVISNE
BRPI1012743A2 (pt) simalica lactona e sua utilização como medicamento
BRPI1013544A2 (pt) compostos com efeito fisiológico
DK2315777T3 (da) Terapeutisk anvendelse af specifik ligand i msrv-associerede sygdomme
IL231589B (en) Composition to be applied to the skin, and use thereof
FI20115180L (fi) Koostumus käytettäväksi sairauden hoidossa